ClinicalTrials.gg
RecruitingNCT07185724Updated Dec 15, 2025

Ketorolac Use and Fresh Embryo Transfer Outcomes

A Phase 4 interventional study of Ketorolac 30 mg IV in Infertility (IVF Patients), Infertility Treatment and Post-op Pain, sponsored by Jessica D. Kresowik. Recruiting at 1 site in United States. Open to female participants aged 18 Years to 37 Years. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Jessica D. Kresowik · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years to 37 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 395 studies in Infertility with a site in United States — 62 open to participants now, 84 under way, 7 of them phase 3. Infertility · United States.

Planned enrollment
73rd of 274
200 · median 84
Started
2025
with 20 others
Phase 4
35 of 395
3 open now
Primary completion
2027-10
later than 44 of 82 live
Registered
379th of 395
by date

Among the 395 studies in Infertility with a site in United States, this one is the 73rd largest by planned enrollment of the 274 interventional ones that give a count, is one of 21 that started in 2025, is one of 35 in phase 4, reaches primary completion later than 44 of the 82 other live ones, and was the 379th registered.

Infertility

2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.

Browse Infertility studies →

Open to participants now

62 of the 395 studies in Infertility with a site in United States are open now. Recruiting first, the newest first:

56 more — sign in →

All 62 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.

This study: 18 Years to 37 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 395 studies in Infertility with a site in United States, or all of them as a file.
02

Study summary

Ketorolac is a medication often used to relieve pain after surgery. In the past, infertility doctors have been cautious about using ketorolac after egg retrieval for patients planning a fresh embryo transfer (usually done 5 days later). The concern was that ketorolac might increase the risk of bleeding or reduce the chances of the embryo implanting in the uterus. This concern comes from how ketorolac works-it blocks certain chemicals in the body (like prostaglandins and thromboxane) that help with blood clotting and play a role in early pregnancy.

However, a large review of past studies found no real evidence that ketorolac increases bleeding risk. In fact, ketorolac is now routinely used for pain relief in IVF cycles where embryos are frozen and not transferred right away. More recent studies from Boston and Chapel Hill have shown that ketorolac provides better pain control and does not appear to harm IVF outcomes, even when embryos are transferred fresh (within the same cycle).

Despite these encouraging findings, many IVF clinics still avoid using ketorolac during fresh cycles because of the theoretical concerns. That's why we need stronger, higher-quality research.

This study aims to fill that gap by conducting a double-blind randomized controlled trial to find out whether giving ketorolac through an IV after egg retrieval affects important IVF outcomes-especially the chance of implantation and live birth-in patients undergoing fresh embryo transfers. Patients who choose to join the study will randomly be placed into one of two groups. One group will get ketorolac (a pain medicine) after an IVF egg retrieval. The other group will not get ketorolac after egg retrieval. Everything else in their IVF care will stay the same as it normally would.

Primary outcome will be implantation rate following fresh embryo transfers in patients receiving ketorolac (30mg IV) vs no ketorolac for post-retrieval analgesia.

Secondary outcomes will include pain scale, narcotics required, time to discharge, need for evaluation w/in 24 hours for pain/bleeding, clinical pregnancy rates, miscarriage rates, and live birth rates following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia.

Read the detailed description

Study Design: double-blind randomized controlled trial Intervention: Ketorolac (30mg intravenous) administration in the immediate post-operative period prior to leaving the procedure room and while patient is still under sedation

Allocation method: 1:1 statistician generated block randomization (blocks of 2, 4, and 6). Patients will be randomized immediately following consent and enrollment.

Materials and Methods: Patients undergoing an IVF autologous cycle at our institution where the female patient is planning on proceeding with a fresh embryo transfer 5 days following ultrasound guided oocyte retrieval will be recruited. Patients may undergo any of our standard controlled ovarian hyperstimulation protocols.

On the day of egg retrieval patients will:

  • Sign the consent and be randomly assigned to one of two groups (usual care plus ketorolac OR usual care without ketorolac).
  • At the end of the retrieval procedure while the patient is still under sedation, the anesthesiology team will administer either usual care plus ketorolac OR usual care without ketorolac through the pre-existing IV line.

Patients IVF care will otherwise remain the same as planned, including:

  • Monitoring in the recovery area as per standard protocol
  • Embryo transfer on day 5 post-retrieval

Investigators will continue to review and collect data from patients' medical records for up to 45 weeks. This will include demographic and medical information, including, but not limited to:

  • age, medical diagnosis, physical exam findings such as height and weight, laboratory testing, and ultrasound results
  • reproductive history including how long patients have been trying to conceive, infertility diagnoses, outcomes of past pregnancies, outcomes of prior infertility evaluation and treatments
  • the types and doses of medications used, types of infertility treatments used, and information about patients' treatment cycles. Treatment cycle information will include, but is not limited to:
  • response to ovarian stimulation,
  • sperm count,
  • embryo development and quality,
  • any post-retrieval evaluations for pain and/or bleeding, and
  • whether or not a pregnancy resulted.
  • narcotic use during recovery, and time to discharge
  • Outcomes from the fresh embryo transfer following retrieval. If patients conceive a pregnancy, then investigators will follow the pregnancy through its resolution. Investigators will collect information about patients:
  • pregnancy hormone levels,
  • confirmation or pregnancy ultrasound findings,
  • information on implantation, clinical pregnancy, miscarriage, and live births.
03

Conditions studied

  • Infertility (IVF Patients)
  • Infertility Treatment
  • Post-op Pain
  • Fresh Embryo Transfer
  • Oocyte Retrieval and Post Operative Pain Control

Keywords

  • IVF
  • post operative pain control
  • oocyte retrieval
  • fresh embryo transfer
  • ketorolac
  • toradol
  • implantation rate
  • live birth rate
  • miscarriage rate
04

Who can participate

Ages eligible
18 Years to 37 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • IVF utilizing autologous oocytes and all sperm sources
  • IVF cycles utilizing ICSI and standard insemination
  • Plan to transfer embryo on day 5
  • below 50

Exclusion criteria

Exclusion Criteria:

-allergies or medical to NSAIDs

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    IV Ketorolac

    Participants randomized to this arm will receive 30mg IV Ketorolac at the conclusion of their oocyte retrieval.

    Drug: Ketorolac 30 mg IV

  • No intervention
    No IV Ketorolac

    Participants randomized to this arm will not receive IV Ketorolac at the conclusion of their oocyte retrieval.

Interventions

  • DrugKetorolacStudies of KetorolacKetorolac pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    We will be evaluating the effect of post-oocyte retrieval ketorolac administration on clinical outcomes in fresh embryo transfer cycles.

06

What researchers measure

Primary outcomes

  1. Implantation Rate

    Implantation rate following fresh embryo transfers in patients receiving ketorolac vs no ketorolac for post-retrieval analgesia. We define implantation rate as the proportion of transferred embryos which resulted in fetal heartbeat seen on ultrasound per patient.

    Time frame: From enrollment to the time of confirmation of pregnancy ultrasound at ~6 weeks post-oocyte retrieval (with or without administration of IV Ketorolac) .

Secondary outcomes

  1. Clinical Pregnancy Rate

    Clinical pregnancy rate is defined as the proportion of patients who had an embryo transfer which resulted in a pregnancy confirmed by an increasing level of human Chorionic Gonadotropin (hCG) and the presence of a gestational sac detected by ultrasound.

    Time frame: From enrollment to the time of confirmation of pregnancy ultrasound at ~6 weeks post-oocyte retrieval (with or without administration of IV Ketorolac) .

  2. Miscarriage Rate

    Miscarriage rate is defined as the percentage of patients with miscarriage after a clinical pregnancy.

    Time frame: From date of enrollment through first documented instance of miscarriage up to 40 weeks.

  3. Live Birth Rate

    Live birth rate is defined as percentage of patients who had a transfer which resulted in a live birth.

    Time frame: From enrollment to the end of pregnancy (~40 weeks) resulting from fresh embryo transfer following the oocyte retrieval in which patient received IV Ketorolac or no IV Ketorolac.

  4. Post-operative Pain

    In the immediate post-operative period, pain will be assessed per standard practice using the visual analog scale. The visual analog scale is used to assess pain on a scale of 0 to 10 with 0 being no pain and 10 being worst pain.

    Time frame: From enrollment until the time of discharge from oocyte retrieval (~2.5 hours).

07

Study locations

1 of 1 sites recruiting
  • UI Health Care Center for Advanced Reproductive Care
    Iowa City, Iowa 52245, United States
    Recruiting
    • Aya Iwamoto, MD · Contactaya-iwamoto@uiowa.edu · (319) 356-1767
    • Jessica Kresowik · Principal investigator
    • Aya Iwamoto · Sub investigator
    • Hakan Duran · Sub investigator
    • Abey Eapen · Sub investigator
    • Abigail Mancuso · Sub investigator
    • Salomeh Salari · Sub investigator
    • Melissa Mathes · Sub investigator
08

References and documents

Publications

  • Mesen TB, Kacemi-Bourhim L, Marshburn PB, Usadi RS, Matthews M, Norton HJ, Hurst BS. The effect of ketorolac on pregnancy rates when used immediately after oocyte retrieval. Fertil Steril. 2013 Sep;100(3):725-8. doi: 10.1016/j.fertnstert.2013.04.048. Epub 2013 May 28. PubMed 23721715 ↗
  • Gobble RM, Hoang HLT, Kachniarz B, Orgill DP. Ketorolac does not increase perioperative bleeding: a meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2014 Mar;133(3):741-755. doi: 10.1097/01.prs.0000438459.60474.b5. PubMed 24572864 ↗
  • Waljee JF, Li L, Brummett CM, Englesbe MJ. Iatrogenic Opioid Dependence in the United States: Are Surgeons the Gatekeepers? Ann Surg. 2017 Apr;265(4):728-730. doi: 10.1097/SLA.0000000000001904. No abstract available. PubMed 27429023 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Oct 2027, 22 months after the start.

Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 22 months is below that.

Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 10, 2025
First posted
Sep 22, 2025
StartActual
Nov 8, 2025
Primary completionEst.
Oct 1, 2027
CompletionEst.
Sep 1, 2028
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07185724
Lead sponsor
Jessica D. Kresowik
Responsible party
Jessica D. Kresowik (Clinical Associate Professor, University of Iowa) — Sponsor-investigator
First posted
Sep 22, 2025
Start date
Nov 8, 2025
Primary completion
Oct 1, 2027 (estimated)
Completion
Sep 1, 2028 (estimated)
Last update
Dec 15, 2025

Study contacts

Jessica Kresowik, MD
Contact
jessica-kresowik@uiowa.edu
563-355-2244

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ketorolac

Start the discussion